CHU
Clermont-Ferrand, 63003, France
NCT Number: NCT00664157
Parkinson'disease is a neurodegenerative disorder characterised by bradykinesia, rigidity, rest tremor and postural instability. Dopaminergic therapy such as L-Dopa and dopamine agonists usually leads to a dramatic improvement of symptoms, but disease progression nevertheless remains inevitable. Bilateral Deep brain stimulation in subthalamic nucleus is now considered the gold standard surgical treatment.
Parkinson'disease mainly affects the nigrostriatal dopaminergic system which is linked to the limbic system and could be responsible of a specific trouble in the recognition in some facial expression.
We hypothesise that patients with Parkinson'disease present a dysfunction of voluntary and automatic treatment of emotional information.
The main purpose of this study is to show if patients with Parkinson'disease present a lack of specific facial expression recognition of emotion and determinate more precisely if this alteration involves the cortical way (high frequency way) or the under cortical way (low frequency way).
We also examine the role of L-Dopa and the deep brain stimulation on emotion perception
Looking for future studies?
Notify Me30 year–75 year
All sexes
Interventional
Not applicable
Clermont-Ferrand, 63003, France
40 patients with an Idiopathic Parkinson's disease divided in two groups :
40 paired healthy volunteers
Inclusion visit :
Neurological evaluations .
Neuropsychological evaluations : MMS, MADRS, MATTIS, BREF, Wisconsin test, Apathy test, Benton….
Ophthalmic visit : VISTECH
Protocol :
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Facial expression recognition test Lexical decisiontest
Time frame: % of exact responses
Time frame: The time to respond
University Hospital, Clermont-Ferrand
Other
Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus .
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01221948
Basal Ganglia Diseases, Brain Diseases
Vienna, Austria
View Trial DetailsNCT05671341
Basal Ganglia Diseases, Brain Diseases
Niğde, Niğde Province, Turkey (Türkiye)
View Trial DetailsNCT02610231
Basal Ganglia Diseases, Brain Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT01968031
Basal Ganglia Diseases, Brain Diseases
Phoenix, Arizona, United States
View Trial Details